|
|
Article: Biovail Receives Canadian Approval for Wellbutrin(R) XL for the Prevention of Seasonal Major Depressive Illness.
- Article from:
- Business Wire
- Article date:
- February 15, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TORONTO -- Biovail Corporation (NYSE: BVF) (TSX: BVF) today announced that it has received a Notice of Compliance from the Therapeutic Products Directorate (TPD) for its supplemental New Drug Submission (sNDS) for a new indication for Wellbutrin[R] XL in Canada - the prevention of major depressive illness with an autumn-winter seasonal pattern.
The approval of Wellbutrin[R] XL for this indication represents a significant milestone for Biovail and for Canadian healthcare, as it represents the first time in Canada that a medication has received an indication for the prevention of this type of major depressive illness. Many patients with major depressive disorder ...